Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06028035 · ClinicalTrials.gov registry record · NA
A Study of Hemp Hull WFI for IBS Diarrhea
A NA study of Irritable Bowel Syndrome-bile Acid Diarrhea, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06028035: Completed NA study of Irritable Bowel Syndrome-bile Acid Diarrhea, sponsored by Mayo Clinic.
NCT06028035 is a NA study of Irritable Bowel Syndrome-bile Acid Diarrhea that has completed, run by Mayo Clinic. The registered enrollment target is 10 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06028035, a NA study of Irritable Bowel Syndrome-bile Acid Diarrhea, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is the effect of a study bar, which contains 15 grams of insoluble dietary fiber total sourced from Hemp hulls, on intestinal permeability in irritable bowel syndrome (IBS)-bile acid diarrhea individuals.
Primary Outcome
Percent urinary excretion of 13\^C-mannitol
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT BB01
Study Locations (1)
Minnesota
- Mayo Clinic Minnesota - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-10-06 |
| Est. Completion | 2024-05-01 |
| Phase | NA |
What the finished NCT06028035 record still lists
NCT06028035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Irritable Bowel Syndrome-bile Acid Diarrhea appearing as the primary indexed condition, and to 1 intervention - of which BB01 is the first listed.
NCT06028035 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06028035 about?
NCT06028035 is a clinical study titled "A Study of Hemp Hull WFI for IBS Diarrhea". The purpose of this study is the effect of a study bar, which contains 15 grams of insoluble dietary fiber total sourced from Hemp hulls, on intestinal permeability in irritable bowel syndrome (IBS)-bile acid diarrhea individuals.
What is the current status of trial NCT06028035?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2023-10-06. Estimated completion is 2024-05-01.
What conditions does trial NCT06028035 study?
This clinical trial studies the following conditions: Irritable Bowel Syndrome-bile Acid Diarrhea.
What interventions are being tested in trial NCT06028035?
The interventions under investigation include: BB01 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06028035?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06028035 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06028035's enrollment target sits among peer trials
10 1927th of 2000 higher than 26 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI